Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: clinical perspective and significance. Issue 1 (4th December 2018)

• Record Type: Journal Article
• Authors: Boyiadzis, Michael M.; Dhodapkar, Madhav V.; Brentjens, Renier J.; Kochenderfer, James N.; Neelapu, Sattva S.; Maus, Marcela V.; Porter, David L.; Maloney, David G.; Grupp, Stephan A.; Mackall, Crystal L.; June, Carl H.; Bishop, Michael R.
• Is Part Of: Journal for immunotherapy of cancer. Volume 6:Issue 1(2018)
• Publication Date: 2018-12-04
• Subjects: Chimeric antigen receptor -- Tisagenlecleucel -- Axicabtagene ciloleucel -- Leukemia -- Lymphoma; Cancer -- Immunotherapy -- Periodicals; Cancer -- Immunological aspects -- Periodicals; Tumors -- Immunological aspects -- Periodicals; Immunotherapy -- Periodicals; 616.99406105
• DOI: 10.1186/s40425-018-0460-5
• Languages: English
• ISSNs: 2051-1426

Abstract

Abstract : Chimeric Antigen Receptor (CAR) T cell therapies – adoptive T cell therapies that have been genetically engineered for a new antigen-specificity - have displayed significant success in treating patients with hematologic malignancies, leading to three recent US Food and Drug Administration approvals. Based on the promise generated from these successes, the field is rapidly evolving to include new disease indications and CAR designs, while simultaneously reviewing and optimizing toxicity and management protocols. As such, this review provides expert perspective on the significance and clinical considerations of CAR T cell therapies in order to provide timely information to clinicians about this revolutionary new therapeutic class.